Guidance for GPs in England on getting your pension record up to date
“One of the biggest challenges that GPs in England face is out of date and inaccurate pension records, with “missing…
NICE has republished its guidance TA878 – Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. The recommendation to extend access to treatment for a broader eligible population (people with diabetes, obesity or heart failure, or aged 70 years or over) has been withdrawn. In line with the original recommendation, Nirmatrelvir plus ritonavir (Paxlovid) is only recommended for patients at highest risk of serious illness as defined in Section 5 of TA878.
These changes mean that some additional groups that were eligible for treatment during the period of the funding variation are no longer subject to a NICE recommendation. These include:
“One of the biggest challenges that GPs in England face is out of date and inaccurate pension records, with “missing…
We have received an update from the BMA in relation to the Deprivation of Liberty Safeguards (DoLS) legislation. As of Monday…
GPC England has agreed in principle to accept proposed amendments to the 2025/26 GP GMS contract following two months of…